Skip to Content

Join the 'Cutaneous T-cell Lymphoma' group to help and get support from people like you.

Cutaneous T-cell Lymphoma News

Related terms: Cancer, Cutaneous T-cell Lymphoma, Lymphoma, Cutaneous T-cell Lymphoma, CTCL

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study ...

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white ...

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is ...

Ceptaris Receives FDA Approval for Valchlor (mechlorethamine) Gel for the Treatment of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma

Posted 27 Aug 2013 by Drugs.com

MALVERN, PA (August 26, 2013) – Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior ...

Study Finds Big Strides Made in Treating Leukemia, Lymphoma in Past Decade

Posted 24 Nov 2010 by Drugs.com

WEDNESDAY, Nov. 24 – Clinicians have made remarkable advances in treating blood cancers with bone marrow and blood stem cell transplants in recent years, significantly reducing the risk of treatment-related complications and death, a new study shows. Between the early 1990s and 2007, there was a 41 percent drop in the overall risk of death in an analysis of more than 2,500 patients treated at ...

Ask a Question

Further Information

Related Condition Support Groups

Mycosis Fungoides, Non-Hodgkin's Lymphoma

Related Drug Support Groups

clobetasol, Targretin, Istodax, bexarotene, methoxsalen, Zolinza, interferon gamma-1b, vorinostat, romidepsin, Actimmune, 8-MOP, Targretin Gel, Uvadex